Orbis Medicines ApS

https://www.orbismedicines.com

LinkedIn: https://www.linkedin.com/company/orbismedicines

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis’ pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. In 2024, Orbis raised a EUR 26 million series seed round co-led by Novo Holdings and Forbion. Proof-of-concept of Orbis’ work has been published in Nature Communications and Nature Chemical Biology. The company is located in Copenhagen, Denmark and Lausanne, Switzerland. *

	Start	2021-09-28 established
	Group	Orbis Medicines (Group)
	Industry	nGen technology platform
	Industry 2	nCycle (fully synthetic macrocycle compound)

	Region	København (Copenhagen)
	Country	Denmark
	Street	215 Nordre Fasanvej
	City	2000 Frederiksberg
		Address record changed: 2025-01-12

Basic data	Employees	n. a.

		* Document for »About Section«: Orbis Medicines ApS. (1/6/25). "Press Release: Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles". Copenhagen.

		Record changed: 2026-05-02

Picture EBD Group Asia Bio Partnering Forum 2026 Singapore 650x200px

More documents for Orbis Medicines (Group)

[1] Orbis Medicines ApS. (1/6/25). "Press Release: Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]